Sharon Bober, PhD

Sharon Bober
 

Founder and Director, Sexual Health Program, Dana-Farber Cancer Institute, Boston, MA.

Dr. Bober is a Senior Psychologist at the Dana-Farber Cancer Institute and the Founding Director of the multi-disciplinary Sexual Health Program at the Dana-Farber Cancer Institute. She is also an Assistant Professor in the Department of Psychiatry at Harvard Medical School. Dr. Bober’s clinical and research efforts focus on developing effective sexual health interventions for cancer patients and survivors, improving doctor-patient communication about sexual function, and addressing late effects for adult survivors of pediatric cancer.


Martin N. Kathrins, MD

Martin N. Kathrins, MD
 

Assistant Professor of Surgery, Harvard Medical School Urologist, Brigham and Women's Hospital, Boston, MA.

Dr. Kathrins is an associate surgeon at Brigham and Women’s Hospital and assistant professor of surgery at Harvard Medical School. Dr. Kathrins received his undergraduate degree from the University of Pennsylvania. He received his medical degree from Columbia University College of Physicians and Surgeons and completed his urology residency at the University of Pennsylvania. He subsequently completed a fellowship in male infertility, andrology and microsurgery at the University of Illinois at Chicago. He is board certified in urology. Dr. Kathrins’ clinical interests include male infertility, hypogonadism, sexual dysfunction and voiding dysfunction. Dr. Kathrins’ research focuses include male factor infertility and the epidemiology of hypogonadism and testosterone supplementation therapy.


Adam Stuart Kibel, MD

Adam Stuart Kibel, MD
 

Chief, Urology, Brigham and Women’s Hospital, Dana-Farber Cancer Institute, Boston, MA.

Dr. Kibel is Chief of Urology at Brigham and Women’s Hospital and Dana-Farber/Brigham and Women’s Cancer Center. In addition, he is an Elliott Carr Culter Professor of Surgery at Harvard University School of Medicine and chairman of the Harvard Urology Residency Program. Dr Kibel received his undergraduate and medical degrees from Cornell University, completed his urology residency at the Harvard Urology Program, and his fellowship at the Brady Urologic Institute at Johns Hopkins. Dr. Kibel is board certified in Urology.


Sherita King, MD

Sherita King, MD
 

Assistant Professor, Department of Surgery: Urology, Medical College of Georgia at Augusta University.

Dr. King is a fellowship-trained and board-certified urologic surgeon specializing in male and female sexual medicine and prosthetic urology. She was raised in Augusta, GA and attended the University of Georgia. She completed medical school and urology residency at the Medical College of Georgia. She continued her training in sexual medicine at San Diego Sexual Medicine. Dr. King is recognized as a center of excellence for penile implants. Her expertise includes erectile dysfunction, Peyronie’s disease (penile curvature), low testosterone, low libido (sex drive), male urinary incontinence, and arousal disorder.


Zachary Klaassen, MD, MSc

Zach Klaassen
 

Urologic Oncologist, Assistant Professor Department of Surgery: Urology, Medical College of Georgia at Augusta University, Georgia Cancer Center.

Dr. Klaassen is a board-certified urologist specializing in Urologic Oncology at the Georgia Cancer Center at the Medical College of Georgia - Augusta University. Director of Clinical Urologic Research, Ronald W. Lewis, MD Endowed Chair for Urologic Education, Residency Program Director and Assistant Professor of Urology, Department of Surgery, Augusta University Health. He is interested in the treatment of patients with urologic malignancies, including prostate, bladder, kidney, testis and penile cancer. He uses both open and minimally invasive (ie. robotic surgery) surgical techniques to treat his patients. Dr. Klaassen believes in taking the cancer journey together with his patients and their families. He focuses on the treatment of not only the cancer, but other side effects of diagnosis/treatment, which may include physical and emotional aspects.


Alicia Morgans, MD, MPH

Alicia Morgans, MD, MPH
 

Genitourinary Medical Oncologist, Medical Director of Survivorship Program at Dana-Farber Cancer Institute, Boston, Massachusetts.

Dr. Morgans is a clinician and physician investigator specializing in investigating complications of systemic therapy for prostate cancer survivors. She has expertise in clinical trials and patient-reported outcome measures, and as well as incorporating patient preferences and beliefs into clinical decision making.


Paul L. Nguyen, MD

Paul L. Nguyen, MD
 

Genitourinary Clinical Center Director, Radiation Oncology, Dana Farber Cancer Institute.

Dr. Nguyen is an internationally-recognized expert in prostate cancer clinical care and research. He has published over 350 original research articles and has national leadership as the vice-chair of the ARS/ACR Appropriateness Criteria Committee for Prostate Cancer and Chair of the Program Committee for the 2019 ASTRO/SUO/ASCO Genitourinary Cancers Symposium. He is the Principal Investigator of the multi-center randomized FORMULA-509 trial and co-chair of the international randomized ENZARAD trial. He serves as the Dana-Farber Brigham Cancer Center Genitourinary Clinical Center Director for Radiation Oncology, Vice-Chair for Clinical Research in the Department of Radiation Oncology, and Professor at Harvard Medical School. He received his AB from Harvard College, MD from Harvard Medical School, and completed his residency at the Harvard Radiation Oncology Program where he served as chief resident.